In contrast, ICI targeting the PD-1/PD-L1 axis was associated with greater antitumor effects and improved clinical outcome (e.g. improved survival) in obese patients suggesting an “Obesity Paradox”16,17 (Fig. 1). This evidence concerns the gene CD274 and obesity disorder.